Your browser doesn't support javascript.
loading
Frontiers in CAR-T cell therapy for autoimmune diseases.
Li, Yan-Ruide; Lyu, Zibai; Chen, Yuning; Fang, Ying; Yang, Lili.
Afiliação
  • Li YR; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: charlie.li@ucla.edu.
  • Lyu Z; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Chen Y; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Fang Y; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Yang L; Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Resea
Trends Pharmacol Sci ; 45(9): 839-857, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39147651
ABSTRACT
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has demonstrated significant success in treating cancers. The potential of CAR-T cells is now being explored in the context of autoimmune diseases. Recent clinical trials have shown sustained and profound elimination of autoreactive B cells by CAR-T cells, leading to promising autoimmune disease control with minimal safety concerns. These encouraging results have inspired further investigation into CAR-T cell applications for a broader range of autoimmune diseases and the development of advanced cell products with improved efficacy and safety. In this review, we discuss the mechanisms by which CAR-T cells target autoimmune conditions, summarize current preclinical models, and highlight ongoing clinical trials, including CAR-T therapy design, clinical outcomes, and challenges. Additionally, we discuss the limitations and future directions of CAR-T therapy in the treatment of autoimmune diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Imunoterapia Adotiva / Receptores de Antígenos Quiméricos Limite: Animals / Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Imunoterapia Adotiva / Receptores de Antígenos Quiméricos Limite: Animals / Humans Idioma: En Revista: Trends Pharmacol Sci Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido